Clinical and pharmacological group: & nbsp

Cardiac glycosides and non-glycosidic cardiotonic agents

Included in the formulation
  • Celanid®
    pills inwards 
  • АТХ:

    C.01.A.A   Glycosides of Digitalis

    C.01.A.A.06   Lanatoside C

    Pharmacodynamics:

    Cardiac glycoside from the leaves of foxglove. It has a blocking effect on the transport sodium / potassium ATP phase, after which the content of sodium ions in cardiomyocytes increases, calcium channels open, calcium enters the cells. An increase in the concentration of sodium accelerates the release of calcium from the sarcoplasmic reticulum and increases its content in the cell, thereby inhibiting the troponin complex, which inhibits the interaction of actin and myosin. The strength and speed of contraction of the cardiac muscle increases regardless of the preliminary stretching of the myocardium - the systole is shortened, becoming energetically economical. Increased myocardial contractility contributes to an increase in the shock volume of the blood.

    Reduction of the end systolic and diastolic volumes of the heart together with an increase in myocardial tone reduces the size of the heart, reducing the need for myocardium in oxygen.

    Carries out a negative chronotropic action, reduces the increased sympathetic activity, increasing the sensitivity of cardiopulmonary baroreceptors.Strengthening the activity of the vagus nerve, has an antiarrhythmic effect due to the elongation of the refractory period and a decrease in the rate of impulses through the atrioventricular node. The effect is improved by direct action on atrioventricular node and sympatholytic effects.

    In patients with excessive stretching of the heart or with normal contractility has a direct vasoconstrictive effect. In patients with chronic heart failure, it produces mediated vasodilating effect, raises diuresis and reduces venous pressure, relieves dyspnea and swelling.

    In toxic and sub-toxic doses has a positive butmotropic effect.

    The initial effect appears after 1.5-2 hours, reaches a maximum after 4-6 hours.

    Pharmacokinetics:

    After oral intake absorbed by 20-60%, binds to plasma proteins by 25-40%. Penetrates through the blood-brain barrier and the placenta. Metabolism in the liver.

    The half-life is 28-36 hours. Elimination of the kidneys in the form of metabolites and mostly unchanged. The ability to cumulate is negligible.

    Indications:

    It is used to treat chronic heart failure, acute left ventricular failure, with atrial flutter, paroxysmal supraventricular tachycardia.

    IX.I30-I52.I48   Atrial fibrillation and flutter

    IX.I30-I52.I50.1   Left ventricular failure

    IX.I30-I52.I50.0   Congestive heart failure

    Contraindications:
    • Atrioventricular block of II degree.
    • Moving full blockade.
    • Glycoside intoxication.
    • Individual intolerance.
    Carefully:

    Atrioventricular block I degree, hypertrophic subaortal stenosis, mitral stenosis, acute myocardial infarction, arteriovenous shunt, amyloidosis of the heart, pericardial tamponade, myocarditis.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Penetrates through the placenta and enters the breast milk. During pregnancy and lactation, the use is contraindicated.

    Dosing and Administration:

    Inside.

    The initial dose of 0.25 mg (1 tablet) - 0.5 mg 3-4 times a day. On 3-5 days after reaching the clinical effect, a maintenance dose of 0.25-0.5 mg.

    To obtain a quick effect, the drug is administered intravenously 0.2-0.4 mg 1-2 times a day.

    The highest daily dose: 1 mg (4 tablets).

    The highest single dose: 0.5 mg (2 tablets).

    Side effects:

    Central and peripheral nervous system: dizziness, headache, delirium, confusion.

    The cardiovascular system: arrhythmia, atrioventricular block.

    The system of hematopoiesis: thrombocytopenic purpura, thrombocythemia.

    Digestive system: anorexia, diarrhea, nausea.

    Sense organs: decreased visual acuity, nosebleeds.

    Allergic reactions.

    Overdose:

    Symptoms: neuritis, manic-depressive psychosis, "flashing of flies" before the eyes, a change in the perception of the color gamut: the coloring of objects in a yellow-green color, necrosis of the intestine, ventricular paroxysmal tachycardia.

    Treatment: symptomatic. Dose reduction or drug cancellation.

    Interaction:

    Catecholamines, diuretics, calcium preparations - increase glycoside intoxication.

    Spironolactone, verapamil, nifedipine, quinidine - increase the concentration of lantozide C in blood plasma.

    Reception antacids reduces absorption of the drug.

    Inotropic effect increases with simultaneous application with riboflavin, thiamine chloride, pyridoxine, folic acid, methionine, inosine, phosphaden, anabolic steroids.

    Special instructions:

    The likelihood of developing intoxication is increased in patients with impaired electrolyte metabolism (hypokalemia, hypernatremia, hypercalcemia), with obesity and in elderly patients.

    The level of digitization is determined by their plasma concentration.

    Instructions
    Up